BEYFORTUS DIN 02537214
Status: Marketed
Holder: SANOFI VACCINES CANADA LTD.
Available to quote
Health Canada record
| Active ingredient(s) | NIRSEVIMAB 100 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intramuscular |
|---|
| Schedule | SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | J06BD08 NIRSEVIMAB |
|---|
| Original market date | 04-Nov-2024 |
|---|
| Current status date | 04-Nov-2024 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Sanofi Vaccines Canada Ltd. — licence 101420, currently licensed, last inspection rating C (2026-02-23).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NIRSEVIMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02537206 | BEYFORTUS | SANOFI VACCINES CANADA LTD. | Solution | NIRSEVIMAB 50 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 32899 | 2024-03-14 | New Drug Submission (NDS) | Administrative ¿ Change to DIN owner. |
| 30540 | 2023-04-19 | New Drug Submission (NDS) | |
Request a quote for BEYFORTUS
How to read a Canadian DIN record